Hemostemix’s Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to Biocardia’s Cardiamp Heart Failure Trial Read More
Hemostemix’s VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments! Read More
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01 Read More
Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants Read More
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval Read More
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 Read More
